Claytons research contributions to PT-141 development include: Principal investigator for pivotal Phase 2 dose-finding trial establishing optimal 1.75 mg dose Lead investigator for RECONNECT Phase 3 trials supporting FDA approval Development of responder analysis methodology for patient-reported outcomes in sexual dysfunction Neurobehavioral research elucidating central mechanisms of sexual desire Extensive publication record on bremelanotide efficacy, safety, and clinical applications Her work has established PT-141 as the second FDA-approved pharmacological treatment for HSDD and the first melanocortin-based therapy for sexual dysfunction, representing a significant advance in womens sexual health treatment options

Research examining human cardiac samples has revealed several key findings: GLP-1R mRNA transcripts have been consistently detected in all four cardiac chambers from human hearts, at levels approximating those in human pancreas [1] Receptor expression is notably absent in cardiac fibroblasts, coronary artery endothelial cells, and vascular smooth muscle cells according to some studies [1] Human GLP-1R expression appears predominantly in cardiomyocytes, albeit at relatively low levels [2] Interestingly, species differences exist in GLP-1R distribution patterns
Intranasal retatrutide represents an emerging area of peptide delivery research that sits at the intersection of convenience and biological reality
Moreover, the PC and GSH contents, along with the activities of the above-mentioned enzymes, were measured via colorimetric assays
Adults: Take 1 capsule daily between meals